Gérard LIZARD is currently Inserm Scientist and Director of the laboratory Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism since 2012 at the Université de Bourgogne (Dijon, France); biochemistry Engineer (National Institute of Applied Sciences (INSA), Lyon, France); PhD - Cellular and Molecular Biology (Lyon, France); PhD - Human Biology / Immunology; Competency for Research Direction (Lyon, France); After seven years of post-doctoral position in Pharmaceutical companies as researcher (1984-1991), he has been recruited by Inserm in 1991; currently senior research fellow Inserm, and director of the team ‘Biochemistry of the peroxisome, inflammation and lipid metabolism’. He managed 20 masters and 21 PhD Theses. He has an expertise in lipids (cholesterol, oxysterols, fatty acids), organelles (peroxisome, mitochondria, lysosome) cell death (apoptosis, autophagy), oxidative stress, inflammation, pharmacology (with a great interest for natural compounds), neurobiology and nanotechnology (targeted therapy). He contributed to several clinical studies as principal and associated investigator.

• Chapter 1. Peroxisome: metabolic functions and biogenesis.- Chapter 2. Peroxisomal Dysfunction and Oxidative Stress in Neurodegenerative Disease: A Bidirectional Crosstalk.- Chapter 3. 7-hydroxycholesterols-induced peroxisomal disorders in glial and microglial cells: potential role in neurodegeneration.- Chapter 4. Peroxisome biogenesis disorders.- Chapter 5. Fatty Acid Oxidation in Peroxisomes: Enzymology, Metabolic Crosstalk with Other Organelles And Peroxisomal Disorders.- Chapter 6. Zellweger syndrome disorders: from severe neonatal disease to atypical adult presentation.- Chapter 7. Heimler Syndrome.- Chapter 8. Potential involvement of peroxisome in multiple sclerosis and Alzheimer’s disease.- Chapter 9. Developmental and degenerative cerebellar pathologies in peroxisomal β-oxidation deficiency.- Chapter 10. A mouse model system to study peroxisomal role in neurodegenerative diseases such as peroxisome biogenesis disorders.- Chapter 11. The Drosophila melanogaster as genetic model system to dissect the mechanisms of disease that lead to neurodegeneration in adrenoleukodystrophy.- Chapter 12. Human peroxisomal 3-keto-acyl-CoA thiolase: tissue expression and metabolic regulation.- Chapter 13. Biological functions of plasmalogens.- Chapter 14. Therapeutic efficacy of plasmalogens for Alzheimer’s disease, Mild Cognitive Impairment and Parkinson’s disease in conjunction with a new hypothesis for the etiology of Alzheimer’s disease.

Gérard LIZARD is currently Inserm Scientist and Director of the laboratory Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism since 2012 at the Université de Bourgogne (Dijon, France); biochemistry Engineer (National Institute of Applied Sciences (INSA), Lyon, France); PhD - Cellular and Molecular Biology (Lyon, France); PhD - Human Biology / Immunology; Competency for Research Direction (Lyon, France); After seven years of post-doctoral position in Pharmaceutical companies as researcher (1984-1991), he has been recruited by Inserm in 1991; currently senior research fellow Inserm, and director of the team ‘Biochemistry of the peroxisome, inflammation and lipid metabolism’. He managed 20 masters and 21 PhD Theses. He has an expertise in lipids (cholesterol, oxysterols, fatty acids), organelles (peroxisome, mitochondria, lysosome) cell death (apoptosis, autophagy), oxidative stress, inflammation, pharmacology (with a great interest for natural compounds), neurobiology and nanotechnology (targeted therapy). He contributed to several clinical studies as principal and associated investigator.

• Chapter 1. Peroxisome: metabolic functions and biogenesis.- Chapter 2. Peroxisomal Dysfunction and Oxidative Stress in Neurodegenerative Disease: A Bidirectional Crosstalk.- Chapter 3. 7-hydroxycholesterols-induced peroxisomal disorders in glial and microglial cells: potential role in neurodegeneration.- Chapter 4. Peroxisome biogenesis disorders.- Chapter 5. Fatty Acid Oxidation in Peroxisomes: Enzymology, Metabolic Crosstalk with Other Organelles And Peroxisomal Disorders.- Chapter 6. Zellweger syndrome disorders: from severe neonatal disease to atypical adult presentation.- Chapter 7. Heimler Syndrome.- Chapter 8. Potential involvement of peroxisome in multiple sclerosis and Alzheimer’s disease.- Chapter 9. Developmental and degenerative cerebellar pathologies in peroxisomal β-oxidation deficiency.- Chapter 10. A mouse model system to study peroxisomal role in neurodegenerative diseases such as peroxisome biogenesis disorders.- Chapter 11. The Drosophila melanogaster as genetic model system to dissect the mechanisms of disease that lead to neurodegeneration in adrenoleukodystrophy.- Chapter 12. Human peroxisomal 3-keto-acyl-CoA thiolase: tissue expression and metabolic regulation.- Chapter 13. Biological functions of plasmalogens.- Chapter 14. Therapeutic efficacy of plasmalogens for Alzheimer’s disease, Mild Cognitive Impairment and Parkinson’s disease in conjunction with a new hypothesis for the etiology of Alzheimer’s disease.

Gérard LIZARD is currently Inserm Scientist and Director of the laboratory Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism since 2012 at the Université de Bourgogne (Dijon, France); biochemistry Engineer (National Institute of Applied Sciences (INSA), Lyon, France); PhD - Cellular and Molecular Biology (Lyon, France); PhD - Human Biology / Immunology; Competency for Research Direction (Lyon, France); After seven years of post-doctoral position in Pharmaceutical companies as researcher (1984-1991), he has been recruited by Inserm in 1991; currently senior research fellow Inserm, and director of the team ‘Biochemistry of the peroxisome, inflammation and lipid metabolism’. He managed 20 masters and 21 PhD Theses. He has an expertise in lipids (cholesterol, oxysterols, fatty acids), organelles (peroxisome, mitochondria, lysosome) cell death (apoptosis, autophagy), oxidative stress, inflammation, pharmacology (with a great interest for natural compounds), neurobiology and nanotechnology (targeted therapy). He contributed to several clinical studies as principal and associated investigator.

• Chapter 1. Peroxisome: metabolic functions and biogenesis.- Chapter 2. Peroxisomal Dysfunction and Oxidative Stress in Neurodegenerative Disease: A Bidirectional Crosstalk.- Chapter 3. 7-hydroxycholesterols-induced peroxisomal disorders in glial and microglial cells: potential role in neurodegeneration.- Chapter 4. Peroxisome biogenesis disorders.- Chapter 5. Fatty Acid Oxidation in Peroxisomes: Enzymology, Metabolic Crosstalk with Other Organelles And Peroxisomal Disorders.- Chapter 6. Zellweger syndrome disorders: from severe neonatal disease to atypical adult presentation.- Chapter 7. Heimler Syndrome.- Chapter 8. Potential involvement of peroxisome in multiple sclerosis and Alzheimer’s disease.- Chapter 9. Developmental and degenerative cerebellar pathologies in peroxisomal β-oxidation deficiency.- Chapter 10. A mouse model system to study peroxisomal role in neurodegenerative diseases such as peroxisome biogenesis disorders.- Chapter 11. The Drosophila melanogaster as genetic model system to dissect the mechanisms of disease that lead to neurodegeneration in adrenoleukodystrophy.- Chapter 12. Human peroxisomal 3-keto-acyl-CoA thiolase: tissue expression and metabolic regulation.- Chapter 13. Biological functions of plasmalogens.- Chapter 14. Therapeutic efficacy of plasmalogens for Alzheimer’s disease, Mild Cognitive Impairment and Parkinson’s disease in conjunction with a new hypothesis for the etiology of Alzheimer’s disease.